Healthcare / Drug Manufacturers - GeneralShenzhen
$5.29
+0.03 (+0.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $22.2M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.7%
↓Gross Margin
55.8%
↑Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.3%
FCF CAGR
—
FCF margin
-1.6%
FCF / Net income
0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $775.7M · net income $-134.7M · FCF $-12.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $775.7M | $775.7M | $795.6M | $895.6M | $884.6M |
| Net Income | $-134.7M | $-134.7M | $-87.8M | $-8.9M | $-68.7M |
| EBITDA | $-80.5M | $-80.5M | $-8.6M | $88.8M | $21.5M |
| EPS | -0.13 | -0.13 | -0.08 | -0.01 | -0.07 |
| Gross Margin | 55.8% | 55.8% | 64.4% | 69.3% | 73.5% |
| Operating Margin | -7.7% | -7.7% | -7.6% | -5.0% | -6.3% |
| Net Margin | -17.4% | -17.4% | -11.0% | -1.0% | -7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.26 | 0.13 | 0.17 |
| Current Ratio | 2.01 | 2.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.1M | $-12.1M | $109.5M | $22.2M | $-11.1M |
| Returns | |||||
| ROE | -7.7% | -7.7% | -4.7% | -0.4% | -3.2% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 37.26 | 169.03 |
| P/B | 3.18 | 3.18 | 1.96 | 1.86 | 1.94 |
| Growth & Yield | |||||
| Revenue Growth | -2.5% | -2.5% | -11.2% | 1.2% | — |
| EPS Growth | -53.4% | -53.4% | -878.8% | 86.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+46.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → -0.13
Residual
+46.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.